Moxifloxacin in situ gel as an adjunct in the treatment of periodontal pocket: A clinico-microbiological study

• Published in: International journal of oral health sciences Vol. 8; no. 1; pp. 19 - 25
• Main Authors: Manjunath, Shaurya, Ravindra, Shivamurthy, Ahmed, Mohammed, Naveen, R, Oswal, Sheetal, Rangaraju, Vivekananda
• Format: Journal Article
• Language: English
• Published: Wolters Kluwer India Pvt. Ltd 01.01.2018
• Subjects: in situ gel; periodontal pockets; Chronic periodontitis; moxifloxacin
• ISSN: 2231-6027; 2348-5094

Context: Periodontal diseases considered as the infectious condition of the periodontium. The prevalence of these diseases can be reduced by mechanical plaque removal along with systemic and locally delivered antimicrobial agents. Moxifloxacin in situ gel was evaluated as an adjunct to scaling and root planing as local drug delivery (LDD) for its efficacy in the treatment of chronic periodontitis. Aims: The aim of the study was to evaluate the efficacy of moxifloxacin as LDD in the treatment of chronic periodontitis. Settings and Design: Study design was randomized control trial. Subjects and Methods: Sixty-seven sites from chronic periodontitis patients of age 25-65 years with a pocket depth of >5 mm, showing radiographic evidence of bone loss were included in the study. The scaling and root planing (SRP) was performed for all the patients and randomly divided into three groups: Group A: SRP + moxifloxacin in situ gel, Group B: SRP + chlorhexidine in situ gel, and Group C: Control group received SRP as monotherapy. The clinical and microbiological parameters were recorded at baseline, 6th week, and 3 months. Statistical Analysis Used: Data were subjected to statistical analysis with repeated analysis of varience and paired t-test using SPSS (V.22) IBM Corporation, Washington, DC, United States) software. Results: All the three groups showed improvement in both clinical and microbial parameters, but at the end of the 3rd month, Group A showed highly significant results in comparison with Group B and Group C. Conclusions: Moxifloxacin showed more gain in clinical attachment level, and reduction in probing depth and in situ gel can be used as a safe vehicle to deliver the drug locally.